Clinical Trial Update: Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) [Phase 2]

View source ↗

Summary

A Phase 2 study of a broad-spectrum HPV vaccine (V502-003) evaluating tolerability, immunogenicity, and efficacy has been withdrawn. The study targeted cervical…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Condyloma Acuminatum

Drugs mentioned

• V502-003 Broad Spectrum HPV Vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer, Condylomata Acuminata | Phase 2 | Status: WITHDRAWN